Dyax (DYAX -33%) plummets today on a dismal Q1 report. Net sales came in at $8.6M, an increase over Q112 sales, but only about half of the $16.01M the Street expected. Net losses were $11.2M or $0.11 per share, relatively in line with Q112, but more than twice the $0.05 per share loss analysts expected. The company blames the miss on weak Kalbitor sales due to a decrease in the number of new patients added and a decline in the number of treatments among existing hereditary angioedema patients.
From other sites
at CNBC.com (Apr 3, 2014)
at CNBC.com (Jun 14, 2012)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs